Yither biotech

简体中文

About Yither Biotech

Caring for life, sharing health and making high quality vaccines.

img

Yither biotech (Shanghai) Co., Ltd (Yither Bio) is located in Zhangjiang Hi-Tech Park, Pudong, Shanghai, and is a wholly-owned subsidiary of Ab&b Bio-Tech CO., LTD.JS . As an innovative bio-enterprise, Yither Biotech's mission is to develop new human vaccines to meet the demand of China and global markets. 

img

Products

Quadrivalent Subunit Influenza Vaccine（0.5ml）
Quadrivalent Subunit Influenza Vaccine（0.5ml）
The Quadrivalent Subunit Influenza Vaccine is developed using the company's own patented technology and is in phase III clinical trial. It has the characteristics of high purity and good safety, especially suitable for children. Currently, no such products are available on the market at home and abroad.
Quadrivalent Influenza Virus Subunit Vaccine (Adjuvanted)
Quadrivalent Influenza Virus Subunit Vaccine (Adjuvanted)
Trivalent Influenza Virus Subunit Vaccine
Trivalent Influenza Virus Subunit Vaccine
Trivalent Influenza Virus Subunit Vaccine (Adjuvanted)
Trivalent Influenza Virus Subunit Vaccine (Adjuvanted)

News Center

The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.
30 2026-06

The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.

Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
More
The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.
08 2026-05

The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.

Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.
More
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global
13 2026-03

Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global

On March 13, 2026, Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) and its parent company Ab&B Bio Tech Co., Ltd. (Ab&B Bio) officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines with Watson Biotech Hong Kong Limited (hereinafter referred to as "Watson Hong Kong") in Taizhou. Both parties announced that they will jointly promote Ab&B Bio's independently developed influenza virus subunit vaccine to set sail overseas. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.
More
E-mail

E-mail

yue.peng@yitherbiotech.com

Whatsapp

Whatsapp

Whatsapp:+86-18521090810

TEL.

+86-021-61639751

TOP

Need more help?

Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.

CONTACT

QUICK LINKS

PRODUCTS

SHARE

Copyright: Yither Biotechnology  Co. Ltd  Powered by:www.30.cn  SEO

Verification 沪ICP备2021028966号-1